Evidence map›Paper›PMID 41329412›Full record

ReviewWiener klinische Wochenschrift2026

Bone metabolism in primary hyperparathyroidism.

Katharina Kerschan-Schindl, Katharina Gelles, Maria Butylina, Richard Crevenna, Peter Pietschmann

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Katharina Kerschan-SchindlDepartment of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Vienna, Austria. Katharina.Kerschan-Schindl@meduniwien.ac.at.ORCID http://orcid.org/0000-0002-1128-7532
Katharina GellesInstitute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Maria ButylinaInstitute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Richard CrevennaDepartment of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Vienna, Austria.
Peter PietschmannInstitute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Funding

Austrian Science Fund P35262-B
6 · The paper itself

Abstract

Primary hyperparathyroidism is a frequent endocrine disorder that affects various organ systems. In this review we present and discuss alterations of bone metabolism in primary hyperparathyroidism. Excessive secretion of parathyroid hormone results in increased bone remodelling with an excess of bone resorption. Consequently, bone mineral density declines, bone quality is compromised and fracture risk increases.Successful surgery for hyperparathyroidism results in a normalization of bone turnover and a decrease of fracture risk. Osteitis fibrosa cystica, a severe bone manifestation of hyperparathyroidism, is observed rarely today.

Indexed as

Bone and BonesHyperparathyroidism, PrimaryBone DensityBone RemodelingBone ResorptionHumansOsteitis Fibrosa CysticaParathyroid HormoneParathyroid HormoneBone mineral densityBone turnover markerFracture riskOsteitis fibrisa cysticaTherapy

Identifiers

PMID41329412
PMCPMC13099684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.